Precision Therapeutics Company Description
Precision Therapeutics helps make the fight against cancer personal. The company develops and markets its ChemoFx tests for use with solid tumor cancers. Physicians can use the test to collect cancer cells from a patient's tumor, then Precision Therapeutics grows the cells further and uses them to try out various cancer treatments in hopes of finding the most effective drug or combination of drugs. While the company has already studied ChemoFx use with ovarian tumors, it is also targeting additional gynecological cancers. Director Joel Adams holds nearly 40% of the company's stock through his Adams Capital Management while director Richard Kollender oversees 21% of the stock through Quaker BioVentures.
View the Comprehensive Company Description for Precision Therapeutics
The Company Description provides a historical perspective of Precision Therapeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Precision Therapeutics's evolution in the marketplace.
